	US 12,076,334 B2
	Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease
Jae Wook Yang, Busan (KR); Jee Young Kim, Busan (KR); Hyuk Woo Lee, Hwaseong-si (KR); Chong-Woo Park, Seoul (KR); Mi Ra Yu, Seoul (KR); Ji Youn Lee, Suwon-si (KR); and Bo Mi Park, Yongin-si (KR)
Assigned to FUTURE MEDICINE CO., LTD., Seoul (KR)
Filed by FUTURE MEDICINE CO., LTD., Seoul (KR)
Filed on Jul. 18, 2022, as Appl. No. 17/866,990.
Application 17/866,990 is a division of application No. 16/767,489, abandoned, previously published as PCT/KR2018/014943, filed on Nov. 29, 2018.
Claims priority of application No. 10-2017-0161545 (KR), filed on Nov. 29, 2017.
Prior Publication US 2023/0095356 A1, Mar. 30, 2023
Int. Cl. A61K 31/7076 (2006.01); A61K 9/00 (2006.01); A61K 47/38 (2006.01); A61P 27/02 (2006.01)

CPC A61K 31/7076 (2013.01) [A61K 9/0048 (2013.01); A61K 47/38 (2013.01); A61P 27/02 (2018.01)]

8 Claims

1. A method of treating optic nerve disease in a subject comprising:

administering a pharmaceutical composition comprising a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient to the subject:

wherein

A is O or S,

R is

a) straight or branched C₁to C₅alkyl unsubstituted, or independently or optionally substituted with 1 or 2 or more C₆to C₁₀aryl,

b) benzyl unsubstituted, or independently or optionally substituted with 1 or 2 or more fluoro, chloro, bromo or straight or branched C₁to C₄alkoxy or

c) benzyl substituted with hydroxycarbonyl, and

Y is H or a halogen element,

wherein the optic nerve disease is selected from the group consisting of ischemic optic neuropathy, traumatic optic neuropathy, and compressive optic neuropathy.